Why did incumbent pharmaceutical firms enter into hundreds of strategic alliances with biotech start-ups?
A. to pursue an unrelated-options perspective without disrupting existing market economics
B. to make small-scale investments in ventures poised to disrupt existing market economics
C. to invest their excess cash flow in the superior technology of the biotech start-ups
D. to share their continuously updated research technology with the biotech start-ups
Answer: to make small-scale investments in ventures poised to disrupt existing market economics